Sveikatos priežiūros specialistams
Prisijunkite, jei norite gauti specialiąją informaciją ir paslaugas
Esate naujokas?
Jei norite sukurti asmeninę paskyrą, užsiregistruokite.

Press Releases

Explore the newest and archived press releases about AOP Orphan, its products, studies and cooperations. We will be happy to answer any questions or comments you may have via publicaffairs@aoporphan.com 

AOP Orphan Statement on SARS-CoV-2 and COVID-19

17. 3. 2020

AOP Orphan hosted an Experts Press Conference at DGHO in Berlin

7. 10. 2019

AOP Orphan hosted Industry Symposium at DGHO in Berlin

7. 10. 2019

AOP Orphan Pharmaceuticals AG, AOP Orphan IP AG and orphanix GmbH join forces to develop RetinolX to prevent bronchopulmonary dysplasia

13. 5. 2019

AOP Orphan announces EU Marketing Authorization for BESREMi® (Ropeginterferon alfa-2b) for rare blood cancer (PV)

21. 2. 2019

AOP Orphan announces positive CHMP opinion for Ropeginterferon alfa-2b/BESREMi®

17. 12. 2018

Stories

MPN Awareness Day on Sep 12th 2019

Prof. Dr. Martin Griesshammer Director, Department of Hematology, Oncology, Hemostaseology and Palliative Medicine, Mühlenkreis clinics

"MPNs is a chronic haematological disease group caused by a stem-cell disorder."

Photos and Infographs

  • Infograph: Integrated care for rare diseases
    Bridging the gap to improve the lives of 30 million people in Europe.
    Infograph: Juggling care and daily life
    The balancing act of the rare disease community.
    Rare diseases seriously impact everyday life.

AOP Orphan Logo 

Contact

We believe that open communication is essential – not just in our day-to-day contact with business associates, but also with prospective partners, media, interested parties who are not yet familiar with AOP Orphan. We will be pleased to answer any questions you may have about the company, its products, studies, pipeline and overall plans.

Press contact

Lena Weissenbacher, BA
Corporate Communication Coordinator
+43 1 503 72 44 0
publicaffairs@aoporphan.com